Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,071.63 +1.08 (+0.02%) Dow
38,460.92 -42.77 (-0.11%) Nasdaq
15,712.75 +16.11 (+0.10%) Bitcoin USD
63,388.13 -3,015.32 (-4.54%) CMC Crypto 200
1,356.76 -25.82 (-1.87%)
Sarepta Therapeutics, Inc. (SRPT)
After hours:
| Previous close | 117.12 |
| Open | 117.66 |
| Bid | 124.11 x 100 |
| Ask | 124.47 x 100 |
| Day's range | 117.21 - 125.13 |
| 52-week range | 55.25 - 159.89 |
| Volume | |
| Avg. volume | 821,675 |
| Market cap | 11.662B |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.80 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 165.89 |
Business WireSarepta Therapeutics to Announce First Quarter 2024 Financial Results
CAMBRIDGE, Mass., April 24, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2024 financial results.
Insider Monkey10 Unstoppable Stocks That Will Make You Richer
In this article, we discuss the 10 unstoppable stocks that will make you richer. To skip the detailed analysis of the economy and market, go directly to the 5 Unstoppable Stocks That Will Make You Richer. On April 12, the week closed out with stocks tumbling as the S&P 500 recorded its worst day since […]
Business WireSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 29, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in March 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
